The pharmaceutical Pfizer filed, this Friday (19), the authorization request to the National Health Surveillance Agency (Anvisa) for emergency use of the vaccine adapted to the Ômicron variant.
Anvisa reported that the vaccine is of the bivalent type, that is, it acts against two strains of the virus.
“In this case, the vaccine is made up of a mixture of the original strain used in the Comirnaty vaccine and the Ômicron strain, subvariant BA.1. The company’s proposal is to use the bivalent vaccine as a booster dose for the population over 12 years of age.
Pfizer reiterated that the new immunizer, of the bivalent type, is adapted to the Omicron BA.1 variant.
“While the current version of the Covid-19 vaccine has consistently been shown to have high levels of effectiveness, protecting against hospitalizations and death with both wild-type and new variants of concern, Pfizer is premised on always looking for new fronts of treatment. approach to fight the pandemic”, said the pharmacist.
Source: CNN Brasil
